Sep 16,2022

Next Generation Sequencing (NGS) Market is expected to generate a revenue of USD 49.76 Billion by 2030, Globally, at 20.82% CAGR

Verified Market Research recently published a report, "Next Generation Sequencing (NGS) Market" By Product And Services (Consumables, Platforms), By Application (Diagnostics, Oncology), By Technology (Sequencing By Synthesis, Targeted Sequencing), By End User (Biotechnology Companies, Hospitals And Clinics), and By Geography.

View Analyst & Ambassador Comments
Go to original news
Sep 22,2022

The Future of Radiology And Artificial Intelligence

There is a lot of hype and plenty of fear around artificial intelligence and its impact on the future of healthcare. There are many signs pointing toward the fact that A.I. will completely move the world of medicine. As deep learning algorithms and narrow A.I. started to buzz especially around the field of medical imaging, many radiologists went into panic mode.

View Analyst & Ambassador Comments
Go to original news
Sep 27,2022

Using Data Science Insights to Make an Impact at LetsGetChecked

At LetsGetChecked, Paulo Sousa, VP of Data Science claims that they leverage a whole host of insights, data, and information to ensure that we are able to seamlessly enable diagnostic testing, virtual care, and personalized treatment plans from the comfort of home. That is why Sousa thinks that the Company utilizes the most progressive business intelligence software and big data analytics platforms to help them explore, analyze and obtain engaging insights based on data.

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

Caris Life Sciences and Flatiron Health Partner to Vastly Increase Access to Most Comprehensive Molecular Testing Available

Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced a partnership with Flatiron Health to integrate Caris’ market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record (EMR) tool. The Molecular Profiling Integration between OncoEMR and Caris enables data-driven clinical decision making for over 2,000 clinicians within the Flatiron network, made up of more than 800 unique cancer care locations across the country. Through the Molecular Profiling Integration, users can easily submit Caris orders with fewer clicks and less data entry, track real-time status updates, and receive the results directly within OncoEMR.

COLLABORATION PARTNERSHIP

#connected device

#platform

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

Flatiron Health Announces Nature Digital Medicine Publication of Machine Learning Development and Evaluation Framework Supporting Prospective Clinical Decisions Applied to Risk Prediction in Oncology

Flatiron Health announced the publication in Nature Digital Medicine of evidence from a machine learning (ML) approach that demonstrates the value of a ML-based clinical tool that can be used to support a clinician’s independent assessment of patient risk, using EHR-derived RWD, to avoid acute care events.

#rwd

#ml

View Analyst & Ambassador Comments
Go to original news
Sep 14,2022

RCTs and RWD: What are They and How do They Complement Each Other in Cancer Research?

Real world data (RWD) is transforming clinical development and it is critical to understand how RWD and randomized clinical trials (RCTs) can work together to bring life saving medicines to patients faster. In this new blog series from COTA and Deloitte, they explore the expanding role of RWD in oncology.

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Sep 15,2022

Jasper Health Expands Access to Virtual Support and Psychosocial Coaching to Enhance the Oncology Care Experience

Jasper Health has announced that its digital solution for oncology care management will be offered as a pilot program through the Evernorth Digital Health Formulary. Through this pilot program, Jasper Health will provide people living with cancer and their care teams access to digital, personalized oncology care management support, including psychosocial coaching, medication management, and symptom tracking.

COLLABORATION PARTNERSHIP

#institution

#coaching

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 27,2022

University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

University of Tübingen, a leading member of Cyber Valley, Europe's largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years. The partners will define cutting-edge research topics at the intersection of health and applications of AI, which will be selected by a joint steering committee. First fellowships have been published here and interested post-doctoral candidates are invited to submit their applications.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 31,2022 TOP STORY

AI Approach may Help Identify Melanoma Survivors who Face a High Risk of Cancer Recurrence

Most deaths from melanoma - the most lethal form of skin cancer - occur in patients who were initially diagnosed with early-stage melanoma and then later experienced a recurrence that is typically not detected until it has spread or metastasized. A team led by investigators at Massachusetts General Hospital (MGH) recently developed an artificial intelligence - based method to predict which patients are most likely to experience a recurrence and are therefore expected to benefit from aggressive treatment. The method was validated in a study published in npj Precision Oncology.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 04,2022

Halma acquires IZI Medical Products

Halma announced that it acquired medical consumable device maker IZI Medical Products for $153.5 million. Maryland-based IZI develops devices used by interventional radiologists and surgeons across acute, hospital-based diagnostic and therapeutic procedures. Its three primary markets consist of image-guided surgery, interventional oncology and interventional spine procedures.

COLLABORATION MERGERS & ACQUISITION

#data & technology

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY